Top > Search of International Patents > Cardioinhibitory/antihypertensive novel endogenous physiologically active peptide

Cardioinhibitory/antihypertensive novel endogenous physiologically active peptide

Foreign code F110005768
File No. Y0461WO
Posted date Sep 14, 2011
Country United States of America
Application number 59947905
Gazette No. 20080267871
Gazette No. 7829526
Date of filing Apr 1, 2005
Gazette Date Oct 30, 2008
Gazette Date Nov 9, 2010
International application number JP2005006510
International publication number WO2005095609
Date of international filing Apr 1, 2005
Date of international publication Oct 13, 2005
Priority data
  • P2004-110463 (Apr 2, 2004) JP
  • 2005WO-JP06510 (Apr 1, 2005) WO
Title Cardioinhibitory/antihypertensive novel endogenous physiologically active peptide
Abstract (US7829526)
The present invention is to provide a novel peptide having a potent hypotensive activity by inhibiting cardiac contractility, a DNA encoding the peptide, an antibody against the peptide, or a cardioinhibitory/hypotensive agent comprising the peptide as an active ingredient.
A search of a genetic data base revealed the presence of a peptide biosynthesized by a processing of unspliced product of TOR2A mRNA.
As a result of functional analysis, a peptide hormone exerting a potent bioactivity and expressed abundantly throughout human organs was found.
The peptide is hydrophobic with a molecular weight of 2664.02 consisting of 24 amino acids (AIFIFISNTGGKQINQVALEAWRS; SEQ ID NO.: 2) and shows a negative inotropism in rat hearts, as well as a marked systemic hypotensive activity.
Scope of claims [claim1]
1. An isolated peptide consisting of any one of the following amino acid sequence (A) to (D): (A) the amino acid sequence shown by SEQ ID NO: 2;
(B) the amino acid sequence shown by position 1 to 20 of SEQ ID NO: 2;
(C) the amino acid sequence shown by position 5 to 24 of SEQ ID NO: 2; and
(D) the amino acid sequence shown by position 2 to 13 of SEQ ID NO: 2.
[claim2]
2. A fusion peptide comprising the peptide according to claim 1 and a marker protein, a peptide tag or a combination thereof.
[claim3]
3. A method for screening a cardioinhibitory factor or hypotensive factor, comprising the steps of administering an effective amount of the peptide according to claim 1 and a test substance to a non-human test animal, measuring a level of cardioinhibitory activity or hypotensive activity, and estimating the test substance as a cardioinhibitory factor in case that cardioinhibitory activity is higher when administering said peptide and said test substance than when administering the same amount of said peptide only, or estimating the test substance as a hypotensive factor in case that hypotensive activity is higher when administering said peptide and said test substance than when administering the same amount of said peptide only.
[claim4]
4. A method for screening an inhibitor of cardioinhibitory activity or an inhibitor of hypotensive activity, comprising the steps of administering an effective amount of the peptide according to claim 1 and a test substance to a non-human test animal, measuring a level of cardioinhibitory or hypotensive activity, and estimating the test substance as an inhibitor of cardioinhibitory activity in case that cardioinhibitory activity is lower when administering said peptide and said test substance than when administering the same amount of said peptide only, or estimating the test substance as an inhibitor of hypotensive activity in case that hypotensive activity is lower when administering the same amount of said peptide and said test substance than when administering said peptide only.
[claim5]
5. A cardioinhibitory/hypotensive agent comprising the peptide according to claim 1 as an active ingredient.
  • Inventor, and Inventor/Applicant
  • SHICHIRI MASAYOSHI
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
IPC(International Patent Classification)
U.S. Cl./(Sub)
  • C07K014/575
  • C07K016/26
  • C07K016/40
  • K61K038/00
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close